Introduction {#s1}
============

Recruitment of EOS to the lung has been reproducibly reported in allergic asthma [@pone.0067560-Bousquet1]. While airway eosinophilia is commonly associated with increased risk for asthma exacerbation, severity, and poor prognosis [@pone.0067560-Broekema1]--[@pone.0067560-Busse1], the precise correlation of EOS to the pathophysiology of asthma remains controversial. Reduction of airway EOS is associated with decline of submucosal matrix protein deposition and airway smooth muscle hyperplasia [@pone.0067560-FloodPage1], [@pone.0067560-Humbles1] suggesting that EOS contribute to airway remodeling. Through the production and release of pro-inflammatory mediators, EOS can amplify the expression of Th1, Th2, and Th17 cytokines and chemokines [@pone.0067560-Spencer1]--[@pone.0067560-Esnault1] indicating they play a role in the adaptive immune response. Recent trials of anti-IL-5 antibodies (mepolizumab and reslizumab) have shown benefits in asthma, particularly in reducing rates of exacerbations [@pone.0067560-Castro1]--[@pone.0067560-Nair1].

One approach to understanding the biology of EOS in asthma is gene expression analysis by microarrays. Initial GeneChip analysis, which was performed using *in vitro* IL-5-activated circulating EOS, identified 66 genes that were up-regulated by IL-5 and predicted to have functions in adhesion, recruitment, activation and survival [@pone.0067560-Temple1]. A subsequent study performed by our group showed that the expression of more than 200 genes was increased *in vitro* in IL-5- and GM-CSF-activated EOS, including the anti-apoptotic serine/threonine protein kinase Pim-1 [@pone.0067560-Bates1], [@pone.0067560-Stout1]. During their egress to the airway, in response to allergen, the phenotype of peripheral blood EOS changes dramatically [@pone.0067560-Bates2]--[@pone.0067560-Johansson1]; however, gene analysis with microarrays of airway EOS has not been explored.

We performed gene expression array analysis on sputum samples obtained following whole lung allergen challenge (WLAC), and on bronchoalveolar lavage (BAL) cells obtained following segmental bronchoprovocation with an allergen (SBP-Ag). These two *in vivo* allergen challenge models are well-established asthma models that lead to eosinophilic airway inflammation [@pone.0067560-Calhoun1]--[@pone.0067560-Boulay1]. Typically SBP-Ag causes EOS to increase in the BAL from ∼0.5% at baseline to ∼70% after allergen challenge [@pone.0067560-Esnault1] while WLAC induces an increase of EOS in sputum from ∼3% to ∼10% [@pone.0067560-Boulay1]--[@pone.0067560-Pin1]. Therefore, we anticipated that analysis of total BAL and sputum cells by microarrays after SBP-Ag and WLAC and purified BAL EOS would facilitate identification of genes specifically expressed by airway EOS.

Materials and Methods {#s2}
=====================

Subjects {#s2a}
--------

The study was approved by the University of Wisconsin-Madison Health Sciences Institutional Review Board (IRB). Informed written consent was obtained from subjects prior to participation. Subjects had a history of mild atopic asthma as defined by at least one positive skin prick test and a history of allergen-induced asthma exacerbation with reversibility to albuterol \>12% and/or a provocative concentration of methacholine producing a 20% fall in FEV~1~ (PC~20~) of \<8 mg/ml. None of the subjects were using inhaled or oral corticosteroids. 10 subjects finished the SBP-Ag protocol and 2 were excluded for lower percentage of EOS in BAL after SBP-Ag (\<67%) or low purity of BAL EOS (\<99%). 18 subjects completed the sputum protocol and 12 were excluded due to having \<500,000 cells, greater than 60% epithelial cells in the sputum, a greater than 2-fold difference in the percentage of epithelial cells pre- and post- WLAC, lack of RNA after extraction, or RNA integrity that was insufficient for microarrays.

Bronchoscopy, SBP-Ag, and Anti-IL-5 Administration {#s2b}
--------------------------------------------------

Detailed methods for bronchoscopy, SBP-Ag, and BAL cell preparation have previously been described [@pone.0067560-Liu4]. A graded inhaled Ag challenge with *Dermatophagoides farinae* (Der p 1, dust mite), *Felis catus domesticus* (Fel d 1, cat) or *Ambrosia artemisiifolia* (Amb a 1, ragweed), obtained from Greer Laboratories (Lenoir, NC, USA) was performed to determine the participant's AgPD~20~ (the provocative dose of Ag leading to a 20% fall in FEV~1~). One month later, a baseline bronchoscopy with BAL (4 × 40 ml aliquots of sterile 0.9% NaCl) was performed followed by administration of Ag at a dose of 20% of the AgPD~20~ into the lavaged segment (BAL V1, [Figure 1](#pone-0067560-g001){ref-type="fig"}). Bronchoscopy with BAL was repeated 48 h later (BAL V2, [Figure 1](#pone-0067560-g001){ref-type="fig"}). One month after the first SBP-Ag, a single dose of anti-IL-5 (750 mg, mepolizumab generously donated by GlaxoSmithKline) was administered intravenously to reduce the number of airway EOS. One month after mepolizumab treatment, the second SBP-Ag was performed with BAL immediately before (BAL V3) and 48 h later (BAL V4). Circulating EOS number was \<100 per µl at the time of the second SBP-Ag (BAL V3). BAL cells were assessed by hemocytometer using Turk's counting solution containing acetic acid and methylene blue and cell differentials were determined on cytospin preparations stained with the Wright-Giemsa-based Hema-3 (ThermoFisher/Thermo Scientific, Rockford, IL, USA). On BAL V2 ([Figure 1](#pone-0067560-g001){ref-type="fig"}), airway EOS were purified from BAL cells using a two-step Percoll gradient as previously described [@pone.0067560-Liu1]. EOS were collected from the 1.085/1.100 g/ml interface.

![Bronchoalveolar lavage and sputum timelines.\
Atopic mild asthmatics underwent bronchoalveolar lavage (BAL) followed by segmental challenge with an allergen (SBP-Ag) on visit 1 (BAL V1). 48 h later on visit 2 (BAL V2), BAL was performed at the site of the challenged segment. One month later, a single dose of mepolizumab was administered. One month after dosing, BALs were repeated both before and after SBP-Ag. BAL cells (BALC) were prepared on visits 1, 2, 3, and 4 and airway EOS (BALEOS) were purified on visit 2. For the induced sputum study, sputum collection was performed followed by a whole lung allergen challenge (WLAC) on visit 1 (sputum V1). Collection of a second induced sputum was done 48 h after WLAC on visit 2 (sputum V2).](pone.0067560.g001){#pone-0067560-g001}

Induced Sputum {#s2c}
--------------

Induced sputum was obtained as previously described [@pone.0067560-Liu3] on visit 1 (sputum V1, [Figure 1](#pone-0067560-g001){ref-type="fig"}) and 48 h after a graded WLAC leading to a 20% fall in FEV~1~ (sputum V2). Briefly, patients inhaled nebulized 3% saline for 5 minutes, rinsed out their mouth and then coughed with collection of the sputum produced. This was repeated a total of three times. The sputum was diluted 1∶1 with PBS. After centrifugation, cytospins were prepared and stained with Giemsa to determine cell distributions. Cells were stored in Trizol solution for RNA purification.

RNA Preparation and Microarray Hybridization {#s2d}
--------------------------------------------

Total RNA was extracted from BAL cells or purified BAL EOS using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA), treated with DNase (RNase-free DNase kit, Qiagen), and RNA from BAL cells were submitted to the University of Wisconsin-Madison Gene Expression Center (Madison, WI) for labeling and hybridization. RNA quality and integrity was evaluated via Agilent 2100 Bioanalyzer platform (Agilent Technologies). Sense-strand cDNA was generated from total RNA using the Ambion Whole Transcript (WT) Target Expression Kit (Life Technologies, Grand Island, NY, USA). Fragmentation and labeling of the single-stranded cDNA was performed using the Affymetrix GeneChip WT Terminal Labeling Kit (Affymetrix, Santa Clara, CA, USA). The labeled cDNAs were hybridized to Human Gene ST 1.0 GeneChips (Affymetrix) according to the manufacturer's protocols.

Induced sputum samples were shipped to Miltenyi Biotech for RNA extraction using standard RNA Trizol extraction protocols. Sample integrity was evaluated via Agilent 2100 Bioanalyzer platform (Agilent Technologies). 50 ng of RNA was amplified and labeled using the Aglient Low Input Quick Amp Labeling Kit (AgilentTechnologies). Hybridization was performed using the Agilent Gene Expression Hybridization Kit to Agilent Whole Human Genome Oligo Microarrays 8X60K for microarray analyses. The Agilent Feature Extraction Software was used to read out and process the microarray image files.

Microarray Data Analysis {#s2e}
------------------------

For BAL cells, raw data (CEL files) were uploaded into ArrayStar software version 4.0 (DNASTAR Inc., Madison, WI, USA) for normalization and statistical analysis. The robust multichip analysis (RMA) algorithm was used for background correction, quantile normalization and median polish summarization. Microarrays are deposited in the Gene Expression Omnibus repository (accession number: GSE46159). Four pairs of data comparisons that might reveal genes up-regulated in BAL cells after allergen challenge with or without mepolizumab were performed. The transcripts were filtered on the basis of ≥2-fold difference. The 99 genes up-regulated by SBP-Ag and decreased 1.5-fold by mepolizumab ([Table S5](#pone.0067560.s005){ref-type="supplementary-material"}) were determined using both the direct fold change between BAL V4 and V2 and the fold change between BAL V2 and V1 divided by the fold change between BAL V4 and V3 (see [Figure 1](#pone-0067560-g001){ref-type="fig"}).

For induced sputum samples, raw data files were analyzed using the Agilent Feature Extraction Software (FES) (Agilent Technologies). The software was used to determine feature intensities, perform background subtraction, reject outliers, and calculate statistical confidences. Microarrays are deposited in the Gene Expression Omnibus repository (accession number: GSE46238).To determine differential gene expression, the data outputted from FES was then analyzed using the Rosetta Resolver gene expression data analysis system (Rosetta Biosoftware). Ratios were calculated as control vs. sample, or before and after allergen challenge, by division of sample intensity through control signal intensity.

Real-time qPCR {#s2f}
--------------

The reverse transcription reaction was performed using the Superscript III system (Invitrogen/Life Technologies, Grand Island, NY, USA). mRNA expression was determined by qPCR using SYBR Green Master Mix (SABiosciences, Frederick, MD, USA) and human IL5RA, LTC4S, FFAR2, CNR2, ARAP3, DAPK2, PRSS33, TNFSF14, IL1R1 and FCER2 (CD23ß) forward and reverse specific primers (see [Table S1](#pone.0067560.s001){ref-type="supplementary-material"} for primer sequences) were designed using Primer Express 3.0 (Applied Biosystems, Carlsbad, CA, USA) and blasted against the human genome to determine specificity using <http://www.ncbi.nlm.nih.gov/tools/primer-blast>. The reference gene, ß-glucuronidase ((GUSB), forward: caggacctgcgcacaagag, reverse: tcgcacagctggggtaag), was used to normalize the samples. Standard curves were performed and efficiencies were determined for each set of primers. Efficiencies ranged between 91 and 96%. Data are expressed as fold change using the comparative cycle threshold (ΔΔCT) method as described previously [@pone.0067560-Esnault1]. The values presented in [Figure 4](#pone-0067560-g004){ref-type="fig"} are fold change = (2^−ΔΔCt^) compared to expression in BAL cells at V1 (before SBP-Ag).

Statistical Analyses {#s2g}
--------------------

To compare expression of genes in total BAL cells and purified BAL EOS by qPCR, data were log transformed and analyzed using the Student's paired *t*-test. Statistical analyses were performed using SigmaPlot 11.0 software package.

Results {#s3}
=======

Gene Expression Analysis in BAL Cells 48 h after SBP-Ag by Microarrays {#s3a}
----------------------------------------------------------------------

While less than 1% of BAL cells were EOS before SBP-Ag, they increased to 73.9% ±4.2 (n = 8) of the total BAL cell population after SBP-Ag. After mepolizumab, SBP-Ag elicited a significant but much attenuated increase in EOS counts compared to before mepolizumab (34% ±9 versus 73.9% ±4.2; p\<0.001, paired *t* test, n = 8) [@pone.0067560-Johansson2]. 2 of 8 subjects ([Figure 2](#pone-0067560-g002){ref-type="fig"}) were randomly chosen for gene expression analysis using a whole human genome transcript microarray. For these 2 subjects, EOS constituted 72 and 74% of the BAL cells after SBP-Ag and were reduced to 24 and 39% of the BAL when SBP-Ag was performed after mepolizumab.

![Heat map generated using Cluster 3.0 and presenting the 299 genes up-regulated by more than 2-fold in BAL cells from both subjects \#1 and \#2, 48 h after SBP-Ag (BAL V2 as shown in [Figure 1](#pone-0067560-g001){ref-type="fig"}) compared to before SBP-Ag (V1).\
Eosinophil-markers (IL5RA, RNASE2, RNASE3 and SIGLEC8) are highlighted. The full list of gene names is presented on [Table S2](#pone.0067560.s002){ref-type="supplementary-material"}.](pone.0067560.g002){#pone-0067560-g002}

In total BAL cells, expression of 299 genes was up-regulated by more than 2-fold 48 h after SBP-Ag ([Figure 2](#pone-0067560-g002){ref-type="fig"} and [Table S2](#pone.0067560.s002){ref-type="supplementary-material"}). In both subjects, 22 transcripts were increased by more than 5-fold ([Table S3](#pone.0067560.s003){ref-type="supplementary-material"}) and 4 transcripts by more than 10-fold (ALOX15, CD1A, CD24 and FAM101B). The 299 genes up-regulated after SBP-Ag included marker genes for EOS (IL5RA, RNASE2, RNASE3, and SIGLEC8), and other genes well-known to be expressed by EOS (ADAM8, CCR3, CD69, CDA, GATA1, HRH4, ICAM3, IL1RL1, LTC4S, OXER1, P2RY2, PADI4, and SIGLEC10). Genes associated with lung remodeling were also found such as metalloproteinase genes (MMP12, MMP9), as well as some IL-13-induced chemokines (CCL13, CCL2) and Th2-associated genes (CCL22, FCER2, and IL1R2) [@pone.0067560-Royce1]--[@pone.0067560-AlMuhsen1]. While expression of genes coding for soluble mediators (e.g. cytokines) were unchanged, receptors for several mediators known to participate in lung fibrosis were up-regulated (CCR2, FGFR2, FLT1, IGF1R, IL1R1 and IL6R) [@pone.0067560-Royce1], [@pone.0067560-AlMuhsen1], [@pone.0067560-Elias1]. 19 transcripts mostly expressed in dendritic cells, lymphocytes or mast cells ([Table S4](#pone.0067560.s004){ref-type="supplementary-material"}), Swissprot research at <http://www.uniprot.org/>) were also included in the 299 transcripts. Further analysis using DAVID Bioinformatics Resources indicated that 31 genes have been previously associated with asthma, allergy or a pulmonary disease (DAVID Bioinformatics Resources 6.7; National Institute of Allergy and Infectious Diseases (NIAID), NIH) ([Table S5](#pone.0067560.s005){ref-type="supplementary-material"}).

99 (33.1%) of the 299 transcripts elevated by more than 2-fold in BAL cells after SBP-Ag were decreased by more than 1.5-fold after reduction of EOS by mepolizumab ([Table S6](#pone.0067560.s006){ref-type="supplementary-material"}). Of note, 1.5- versus 2-fold reduction was chosen because mepolizumab decreased EOS percentage in BAL cells by ∼50%. Among the 99 genes whose expression was down-regulated after SBP-Ag are the well-known EOS-specific genes (IL5RA, RNASE2, RNASE3 and SIGLEC8) and all the other transcripts mentioned above as previously known to be expressed by EOS (ADAM8, CD69, GATA1, HRH4, ICAM3, IL1RL1, LTC4S, OXER1, P2RY2, PADI4 and SIGLEC10) except for CCR3. In addition, other genes that are not known to be expressed by EOS were down-regulated by mepolizumab. Whether these genes are expressed by other cell types (lymphocytes, dendritic cells, macrophages, or mast cells) that are affected directly or indirectly by the lack of IL-5 or the reduction of EOS or directly expressed by EOS is not known.

Identification of EOS-associated Genes by Microarray Using Induced Sputum after WLAC {#s3b}
------------------------------------------------------------------------------------

Sputum cells from 6 subjects were analyzed by a whole genome transcript microarray. WLAC increased the percentage of EOS in sputum from 2.0 to 8.2% (p\<0.001). Marker genes for EOS (RNASE2, RNASE3, IL5RA and SIGLEC8) were increased by more than 2-fold after WLAC in 3 of the 6 subjects involved in this analysis. Sputum samples from these 3 individuals allowed us to establish a list of 365 EOS-associated genes whose expression was increased by more than 1.5-fold after WLAC ([Table 1](#pone-0067560-t001){ref-type="table"}). In addition to the original EOS markers (RNASE2, RNASE3, IL5RA and SIGLEC8), the 365 transcripts ([Table 1](#pone-0067560-t001){ref-type="table"}) included some other well-known genes expressed by EOS. In fact, 11 of the 13 genes (ADAM8, CCR3, CD69, CDA, HRH4, ICAM3, IL1RL1, LTC4S, P2RY2, PADI4 and SIGLEC10) known to be expressed by EOS and up-regulated in BAL cells after SBP-Ag ([Table S2](#pone.0067560.s002){ref-type="supplementary-material"}) were also seen in sputum after WLAC.

10.1371/journal.pone.0067560.t001

###### EOS-associated genes in sputum after WLAC.

![](pone.0067560.t001){#pone-0067560-t001-1}

  ---------- ------------ ---------- ----------- ------------ ---------- ---------- -----------
  AATK           CD48       DNAJB5      GPR56       KCNK5       NKX6-2     RAB37      ST6GAL1
  ABCB1          CD69      DNASE1L3     GPR84       KCNMB4       NOV       RAB3D      ST8SIA4
  ABLIM2         CD93       DUSP2       GPR97       KCNN4       NPDC1      RASAL1      STAB1
  ACAP1          CDA         DYSF        GPT        KCTD15      NRARP      RASSF2      SULF2
  ACOX2         CDKN1C       ECE1       GRASP       KIF21B       NRG1      RASSF5      SYNE1
  ACPP          CDRT8        EGR3       GRB10       KLF10       NTRK1       RD3        SYNE2
  ADAM19        CECR6        EGR4       GSDMA     KRTAP19-1      ODF4      RGAG4       TAC4
  ADAM28        CHI3L1      EIF2C2      HAS1         LBH        OLIG1       RGL4       TAGAP
  ADAM8         CHST15       EMB        HBA2       LGALS12      OLIG2      RGS16      TAS2R50
  ADAMTS10      CHST2       EMR4P        HBB        LGALS2      OSBPL3      RGS2      TBC1D3B
  ADORA2A       CHSY1        ENHO        HBD        LIMK2        OSM        RHOH       TESC
  AGER           CLC        ENPP1       HCG27       LPPR2       P2RY14     RNASE2      TET2
  AGPAT9       CLEC10A      ENPP2       HDAC4        LRG1       P2RY2      RNASE3      TGM2
  ALPL          CLEC4F      EPHB3        HDC        LTC4S       P2RY6      RNASE6      THBS4
  AMPD2         CLEC4G       ETV3        HGF         LTF        PADI2      RNF19B      TIAM2
  ANKH          CLEC5A      F13A1       HHIP         LY9        PADI4      RUFY4       TIMP1
  APOBEC3B      CMTM2      FAM101B      HIC1       MARCKSL1      PAK1      RUNX2      TMEM154
  ARAP3          CNR2      FAM198B      HIF1A       MAST4       PALLD       RYBP      TMEM156
  AREG         COL18A1      FAM20A      HIP1R        MATK       PARM1      S100B      TMEM71
  ASB2           COMP       FAM46B    HIST1H1D      MBOAT7      PDCD1      S1PR1     TNFRSF10C
  ASGR2         CORO1A      FAM65B    HIST1H1E      MCTP2       PDE2A      SATB1      TNFSF14
  ATHL1        CREB3L3      FAM83A    HIST1H2AC     MECOM      PGLYRP1     SCHIP1      TPCN1
  ATL2          CREB5        FCAR     HIST1H2AE      MGAM       PHF19      SCNN1D     TREML2
  ATP2A3      CSGALNACT2    FCER1A    HIST1H2BO    MGC24103     PHLDB1      SDS       TRERF1
  ATP8B4         CST7       FCER2     HIST1H4A       MMP1       PIK3R5      SELL       TRPM6
  B3GNT8       CTTNBP2      FCGR2B    HIST2H2BE     MMP10       PIK3R6     SEMA4B     TSPAN18
  B4GALNT3      CX3CR1       FCN1       HSPA6       MMP12      PIP5K1B     SEMA7A      TTYH2
  BIRC3         CXCR1       FFAR2       ICAM3       MMP25       PLAUR     SIGLEC10      VDR
  CACNA1E       CXCR2       FFAR3      IFITM1        MMP7        PLD4     SIGLEC8      VEGFA
  CACNA2D3     CXCR2P1      FGF11       IGFL1       MPZL3      PLEKHG2    SLC16A10     VENTX
  CALCRL        CYP1B1       FHL3       IL10         MRC2       PLUNC     SLC24A3      VNN2
  CAMK1        CYP4F12     FLJ11710    IL18R1       MRVI1      PPP1R14A   SLC26A8      VSTM1
  CASS4        CYSLTR2      FNDC1       IL1R1       MSRB3      PPP2R2C    SLC2A13      WNT5A
  CBFA2T3       CYTIP        FRY        IL1R2        MST4       PRDM1      SLC3A1      WTAP
  CCL17         DAB2IP       FZD2      IL1RAP        MT1G       PRKCB     SLC40A1      XYLT1
  CCL26         DACH1      GADD45A     IL1RL1       MTVR2       PRSS33    SLC6A10P     YPEL3
  CCR3          DAPK2       GAGE7       IL21R        MXD1      PSTPIP1     SLC6A8     ZBTB46
  CD177         DCHS1        GAS6        IL4        NCAM2       PTGIR      SLC7A5     ZBTB46
  CD1A         DEFB122      GATA2       IL5RA     NCRNA00085    PTGS2      SNAI1      ZDHHC18
  CD1B         DEFB130      GCOM1       IL6R      NCRNA00152    PTP4A3     SNHG3      ZDHHC8
  CD1C          DENND3      GFRA2      INSIG1     NCRNA00287    PTPN7      SOCS2      ZNF395
  CD1E           DGKA        GGT5       IRX6         NDE1       PVRL2      SORBS1     ZNF469
  CD207          DGKD       GLYCTK    ITGB1BP2      NDEL1        PXN       SORL1      ZNF507
  CD209         DIRAS1      GPR160     JHDM1D       NECAB2     PYROXD2     SPATA9   
  CD226         DNAH17      GPR183      KCNH2       NHSL2        QPCT      SPNS3    
  CD300LB       DNAJB1      GPR35      KCNJ15        NKD1       RAB33A     SPOCK1   
  ---------- ------------ ---------- ----------- ------------ ---------- ---------- -----------

365 genes upregulated by more than 1.5 in each of the 3 subjects with high levels of EOS-characterizing genes (IL5RA, RNASE2, RNASE3 and SIGLEC8) after WLAC.

Identification of Airway EOS Gene Expression {#s3c}
--------------------------------------------

We have utilized 3 airway models that either augmented or reduced the EOS population, and defined genes concomitantly expressed with markers of EOS genes in the context of allergen challenges *in vivo*. [Figure 3](#pone-0067560-g003){ref-type="fig"} shows that 168 (111+57) (46%) of the 365 EOS-associated genes in sputum were also identified in the 299 genes up-regulated in BAL cells. This suggests that despite distinct anatomical sites and provocative protocols, infiltrating EOS express a consistent group of transcripts. Furthermore, the intersection of these 2 sets with the genes decreased by mepolizumab identified a group of 57 genes ([Figure 3](#pone-0067560-g003){ref-type="fig"} and [Table 2](#pone-0067560-t002){ref-type="table"}). We propose that this intersection represents a stringent selection for gene expression by airway EOS. A literature search in PubMed (<http://www.ncbi.nlm.nih.gov/pubmed/>) indicates that only 16 of the 57 genes (28%) have been previously linked to EOS. Therefore, 41 genes (\>70%) in this subset have not previously been associated with EOS.

![Venn diagram identifying 57 genes highly associated with airway EOS after an allergen challenge.\
57 genes defined at the intersection of genes up-regulated in BAL cells after SPB-Ag, down-regulated when SBP-Ag was performed following mepolizumab, and part of the EOS-associated genes in the sputum following WLAC.](pone.0067560.g003){#pone-0067560-g003}

10.1371/journal.pone.0067560.t002

###### 57 genes upregulated in BAL cells after SBP-AG, down-regulated when SBP-Ag was performed following mepolizumab, and part of the EOS-associated genes in sputum after WLAC.

![](pone.0067560.t002){#pone-0067560-t002-2}

  --------------------------------------------- --------------------------------------------- --------------------------------------------- --------------------------------------------- ---------------------------------------------- -----------------------------------------------
  ADAM28                                         **CNR2** [\*](#nt102){ref-type="table-fn"}                       FFAR3                                        LGALS12                     **PRSS33** [\*](#nt102){ref-type="table-fn"}                       SPNS3
  ADAM8                                                            CORO1A                                         FHL3                       **LTC4S** [\*](#nt102){ref-type="table-fn"}                      RAB37                                           TESC
  **ARAP3** [\*](#nt102){ref-type="table-fn"}                      CYP4F12                                        GGT5                                          MCTP2                                         RAB3D                       **TNFSF14** [\*](#nt102){ref-type="table-fn"}
  ASB2                                                              DACH1                                         GPR56                                         MMP25                                          RD3                                           TREML2
  ATP2A3                                         **DAPK2** [\*](#nt102){ref-type="table-fn"}                      GPR97                                         NHSL2                                         RNASE2                                          TRPM6
  CASS4                                                             DGKD                                          ICAM3                                         P2RY2                                         RNASE3                                         TSPAN18
  CD300LB                                                           EMR4P                                        IFITM1                                         PADI2                                        SIGLEC10                                         VSTM1
  CD69                                                             FAM101B                                       IL1RL1                                         PADI4                                        SIGLEC8                     
  CDA                                                              FAM65B                      **IL5RA** [\*](#nt102){ref-type="table-fn"}                     PGLYRP1                                       SLC24A3                     
  CHST15                                         **FFAR2** [\*](#nt102){ref-type="table-fn"}                     KIF21B                                        PIK3R6                                         SORL1                      
  --------------------------------------------- --------------------------------------------- --------------------------------------------- --------------------------------------------- ---------------------------------------------- -----------------------------------------------

genes chosen for validation of the list by qPCR.

IL5RA, RNASE2, RNASE3 and SIGLEC8 are known markers of EOS.

Validation of the Airway EOS-associated Genes {#s3d}
---------------------------------------------

To validate the expression of these genes by airway EOS, we performed qPCR for 8 of the 57 genes ([Table 2](#pone-0067560-t002){ref-type="table"}). The samples from the 6 subjects not used in the microarray analyses were analyzed by qPCR. Gene expression in highly purified BAL EOS (BAL V2, see [Figure 1](#pone-0067560-g001){ref-type="fig"}) and total BAL cells after SBP-Ag before (BAL V2) and after mepolizumab infusion (BAL V4) are presented as fold change (2^−ΔΔCt^ method) compared to gene expression in BAL cells before SBP-Ag (BAL V1). Initially, 2 established genes expressed by EOS were chosen as controls (IL5RA and LTCS4). As shown in [Figure 4A](#pone-0067560-g004){ref-type="fig"}, expression of both genes was highly up-regulated by SBP-Ag, and strongly decreased (\>80%) by mepolizumab. Both genes displayed very high levels in pure BAL EOS compared to total BAL cells, suggesting that EOS are likely the main source of IL5RA and LTCS4 in BAL cells obtained after SBP-Ag. In [Figure 4B](#pone-0067560-g004){ref-type="fig"}, FFAR2 and CNR2 were selected as genes that have been connected with asthma and/or allergy and have been reported to be expressed by EOS [@pone.0067560-Kishimoto1], [@pone.0067560-Maslowski1]. Both genes exhibited the same profile as IL5RA and LTCS4, indicating that EOS are also an important source of FFAR2 and CNR2 in BAL cells. In addition, 4 of the 41 genes for which expression in EOS has not previously been described were randomly selected. As shown in [Figure 4C](#pone-0067560-g004){ref-type="fig"}, all 4 genes (ARAP3, DAPK2, PRSS33 and TNFSF14) presented the same profile of expression as IL5RA, LTCS4, FFAR2 and CNR2 demonstrating that these transcripts are highly expressed in airway EOS. IL1R1 and FCER2 (CD23ß) were chosen as negative controls as they were up-regulated in unseparated BAL cells after SBP-Ag ([Table S2](#pone.0067560.s002){ref-type="supplementary-material"}) and part of the EOS-associated genes as established in sputum ([Table 2](#pone-0067560-t002){ref-type="table"}), but were not affected by mepolizumab ([Table S6](#pone.0067560.s006){ref-type="supplementary-material"}). Conversely to IL5RA, LTCS4, FFAR2, CNR2, ARAP3, DAPK2, PRSS33 and TNFSF14, IL1R1 and FCER2 displayed very low expression in BAL EOS compared to total BAL cells ([Figure 4D](#pone-0067560-g004){ref-type="fig"}). [Figure 4](#pone-0067560-g004){ref-type="fig"} validates the data obtained by microarrays and demonstrates that BAL EOS are likely the source of the 57 genes that increased post SBP-Ag in BAL cells. Using DAVID Bioinformatics Resources, genes were clustered according to their known functions. Six genes have been associated with a respiratory disease, 7 genes produce secreted proteins and 27 genes code for plasma membrane protein. Some other important clusters included cell adhesion (7 genes), immune and defense response (6 genes), and receptors for a variety of stimuli such as carbohydrates and nucleotides (15 genes) ([Table S7](#pone.0067560.s007){ref-type="supplementary-material"}).

![Validation by qPCR of the 57 genes associated with airway EOS after airway allergen challenge.\
qPCR was performed on BAL cells before SBP-Ag (BAL V1 as shown on [Figure 1](#pone-0067560-g001){ref-type="fig"}), 48 h after allergen with (V4) or without mepolizumab treatment (V2), and on purified BAL EOS (BALEOS) after allergen challenge (no mepolizumab, V2). Fold changes compared to expression in BAL cells before allergen challenge and mepolizumab (V1) are presented. Box plots depict the median and the interquartile range between the 25^th^ and the 75^th^ percentiles. 6 subjects are included in each group and means are presented in parentheses. \*\* indicates that mRNA level in BAL cells is significantly decreased by mepolizumab compared to BAL cells on V2 (p\<0.01). \# indicates that mRNA level in BAL EOS at V2 is significantly higher or lower compared to total BAL cells on V2 (^\#^, p\<0.05; ^\#\#^, P\<0.01: ^\#\#\#^, P\<0.001).](pone.0067560.g004){#pone-0067560-g004}

Discussion {#s4}
==========

We have used a unique approach combining 3 whole genome expression microarrays (sputum cells after WLAC, BAL cells after SBP-Ag, and BAL cells after mepolizumab and SBP-Ag) to identify 57 genes highly expressed by airway EOS after an allergen challenge. We demonstrated that EOS are likely the main source of these 57 genes expressed by total BAL cells. The 57 genes included genes such as CD69, IL5RA, LTC4S, RNASE2, RNASE3, SIGLEC8, ADAM8, CDA, ICAM3, IL1RL1 (ST2), and P2RY2 that are known to be expressed in EOS, and other genes not previously linked to EOS. Cluster analysis indicated these genes might have an impact on EOS migration and activation, as well as the innate and adaptive immune responses.

Of the 57 transcripts associated with airway EOS, 16 have been previously detected in circulating EOS, including IL1RL1, CNR2, and FFAR2. IL1RL1 (also known as ST2) is the receptor for IL-33, a cytokine that is released following epithelial damage during an allergic reaction. IL-33 can activate CD4^+^ T cells, type-2 innate lymphoid cells, and mast cells, as well as EOS [@pone.0067560-Cherry1]. The function of IL-33 on circulating EOS includes induction of degranulation, cytokine release, and increased survival. *In vivo*, blockade of the IL-33/IL1RL1 pathway reduces allergic inflammation and airway responsiveness [@pone.0067560-Kearley1]. Our study suggests that EOS might be the main source of IL-33 receptor among the airway inflammatory cells present after SBP-Ag, and EOS could contribute to IL-33-mediated effects in allergic asthma. CNR2 (also called CB2 receptor) is the cannabinoid receptor expressed in lymphoid organs [@pone.0067560-Munro1]. CNR2 is known to be expressed by circulating EOS, and an endogenous ligand (2-arachidonoylglycerol) induces EOS migration [@pone.0067560-Oka1]. In mice, genetic deletion of Cnr2 exacerbated contact allergic inflammation and influenza-induced excessive airway injury possibly via induction of pro-inflammatory and pro-remodeling mediators (IL-17, IL-13, TNF-α, GM-CSF) [@pone.0067560-Karsak1], [@pone.0067560-Karmaus1]. CNR2 agonists reduced bronchoconstriction, mast cell degranulation and pulmonary inflammation in guinea pigs [@pone.0067560-Giannini1]. Another endogenous CNR2 ligand, anandamide is increased in BAL fluids after SBP-Ag, and correlated with the number of EOS in the airway [@pone.0067560-Zoerner1]. Finally, FFAR2 expression by EOS has only been reported once [@pone.0067560-Maslowski1]. FFAR2 (also known as GPR43) is a lipid G-protein coupled receptor for short-chain fatty acids that is produced by bacteria after fermentation of dietary fibers. Interestingly, the lack of FFAR2 led to unresolved inflammation in several animal models of inflammation, including allergen-induced airway inflammation [@pone.0067560-Maslowski1], suggesting FFAR2 activation by short-chain fatty acids would be beneficial to reduce asthma.

One example of potentially novel EOS-derived mediators is TNFSF14 (also called LIGHT), a membrane-expressed or secreted protein that interacts with TNFRSF14 membrane receptor (HVEM), and was characterized as a co-stimulatory ligand for lymphoid cells [@pone.0067560-delRio1]. As most of the co-stimulatory members of the TNF/TNFR superfamily, TNFSF14 has been studied for its impact on autoimmune disease and transplant rejection [@pone.0067560-delRio1]. More recently, LIGHT has been implicated in induction of airway fibrosis and smooth muscle hyperplasia via TGF-ß and IL-13 production in an allergic animal model [@pone.0067560-Doherty1]. Interestingly, in human sputum, LIGHT protein level has been associated with lower lung function (FEV~1%~ predicted) [@pone.0067560-Hastie1].

Another example of novel mediators in human EOS is PGLYRP1 or PGRP-S (also called Tag7), which recognizes bacterial peptidoglycan and has an antibacterial function [@pone.0067560-Osanai1]. PGLYRP1 is a 21Kd protein with a signal peptide for secretion. While PGLYRP1 has not been described in human EOS, bovine and mouse EOS are known to express and store the bovine and murine ortholog of PGLYRP1 [@pone.0067560-Tydell1], [@pone.0067560-Park1]. In addition, to its antimicrobial function, several mouse models using PGLYRP1 knock-out, have demonstrated both an anti-inflammatory role for PGLYRP1 that down-regulated the production of type-1 cytokines and chemokines [@pone.0067560-Saha1], and a pro-inflammatory role in atopic dermatitis, contact dermatitis, and pulmonary inflammation models promoting the Th1, Th2 and Th17 response [@pone.0067560-Park2], [@pone.0067560-Park3]. Also, through its interaction with Hsp70 on cytotoxic lymphocytes, PGLYRP1 possesses anti-tumor cell activity [@pone.0067560-Sashchenko1].

Another intriguing gene is PRSS33 (also called Protease EOS). This member of the trypsin-like serine proteases has been described to be predominantly produced by macrophages [@pone.0067560-Chen1]. However, an international patent has described PRSS33 as expressed by EOS as well (Pub. No.: WO/2001/016290). Proteases have crucial roles in maintaining homeostasis and regulating inflammation and immune reactions, thus their expression in EOS is under active investigation. For instance, PRSS21 (esp-1) has been found in EOS but not in neutrophils [@pone.0067560-Inoue1], and we have shown very recently that EOS could generate high amounts of another protease, MMP-9 [@pone.0067560-Kelly1]. Yet, the production of PRSS33 by human EOS remains uncertain.

There is little overlap between airway EOS genes described in the present study and previous microarrays using *in vitro* activated blood EOS. *In vitro*, IL-5 induced the up-regulation of CD69 by blood EOS [@pone.0067560-Temple1], [@pone.0067560-Bates1]. Surprisingly, CD69 was the only common gene between our 57 EOS-associated genes and the genes up-regulated by IL-5 or GM-CSF in these 2 previous studies. This suggests that a short-term *in vitro* activation using IL-5 or GM-CSF might not be an adequate model to reflect *in vivo* EOS activation after an allergen challenge. In addition, the present study analyzed the presence of genes associated with eosinophilia while the 2 previous studies analyzed genes that are cytokine-induced. Thus, in addition to their exposure to cytokines, airway EOS likely become activated as a result of their transmigration out of the blood and through the tissues. Future studies will be required to determine if the 57 genes are inducible or constitutively expressed by airway EOS. Comparison of gene expression in airway EOS after allergen challenge with blood EOS obtained from individuals who do not receive challenge would provide information on the inducible versus constitutive expression of these genes.

In a study by Nakajima et al. [@pone.0067560-Nakajima1], microarray analysis examined EOS-specific transcripts by comparison to other nucleated peripheral blood cells. Among the 30 EOS-specific genes, 3 were present in our list of 57 genes (RNASE2, IL5RA and CNR2). 11 of the 30 genes were also up-regulated in our BAL cells after SBP-Ag including GPR44, ALOX15, P2RY14, IDO1, ADORA3, CAMK1, CCR3 and P2RY10; while 10 of the 30 genes were part of the EOS-associated genes in induced sputum (CLC, PLAUR, MARCKSL1, P2RY14, CAMK1, CCR3, and OLIG2).

Gene expression analysis by microarrays has been previously performed on bronchial biopsies from asthmatic patients and on airway epithelial cells [@pone.0067560-Laprise1], [@pone.0067560-Lilly1] but microarray analysis using BAL cells after *in vivo* challenge has not been reported. In our whole genome expression analysis, 299 genes were up-regulated after SBP-Ag in BAL cells. Cluster analysis by DAVID Bioinformatics Resources identified 36 genes involved in defense, immune, or wound-healing responses, 32 genes implicated in cell adhesion or locomotion, 23 genes that regulate transcription, 21 genes associated with apoptosis and 12 genes that are part of the second-messenger-mediated signaling. Importantly, the EOS markers (RNASE2 and RNASE3, also called EDN and ECP) as well as 15 other well-known EOS-associated genes were up-regulated concomitantly with EOS accumulation in the airway following SBP-Ag. Of these 17 genes, all but CCR3 were decreased by the mepolizumab infusion. Among the 13 genes up-regulated by SBP-Ag and related to lung remodeling (CCL2, CCL13, CCL22, CCR2, FCER2, FGFR2, FLT1, IGF1R, IL1R1, IL1R2, IL6R, MMP9 and MMP12), 11 of them were unchanged following mepolizumab. This suggests that in this model mepolizumab did not impact expression of remodeling-associated genes.

Potential limitations of this study include the inability to assess gene expression in non-hematopoietic airway cells (including epithelial cells) or to detect by microarray transcripts, such as cytokines, that are in low abundance. Unlike microarray analysis, qPCR allowed detection of IL-13 and IL-17A in BAL after SBP-Ag [@pone.0067560-Esnault1]. This suggests that some genes might have been excluded from the final eosinophilic genes and that the list of 57 genes is not an exhaustive inventory. Finally, it is important to note that a portion of the genes that are not affected by mepolizumab may in fact represent genes associated with a distinct phenotype of eosinophils that were recruited to or differentiated in the airway following administration of mepolizumab.

In conclusion, we have identified 57 genes highly expressed *in vivo* by airway EOS (BAL and sputum). Most of the 57 genes have not been previously studied in EOS and are important candidates to understand tissue EOS biology and to find new targets for therapies associated with an excessive eosinophilic response.
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